Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

High-Throughput Drug Screening Identifies Pyrimethamine As a Potent and Selective Inhibitor of Acute Myeloid Leukemia

Amit Sharma, PhD, Nidhi Jyotsana, Courteney K. Lai, BSc, Anuhar Chaturvedi, PhD, Kerstin Görlich, Cecilia Murphy, Jan E. Blanchard, Arnold Ganser, Eric Brown, John A. Hassell, R. Keith Humphries, MD PhD, Michael A Morgan, PhD, Michael Heuser, MD

Blood (2014) 124 (21): 2304.

https://doi.org/10.1182/blood.V124.21.2304.2304

Published: 2014

Journal Articles

NADH Dehydrogenase Subunit 4 ( ND4 ) Mutations in Pediatric Acute Myeloid Leukemia

Michael A Morgan, PhD, Birgit Markus, MD, Malou Hermkens, Frederik Damm, MD, Katarina Reinhardt, PhD, Martin Zimmermann, PhD, Iris H.I.M. Hollink, MD, PhD, MM van den Heuvel-Eibrink, MD, PhD, C. Michel Zwaan, MD, PhD, Felicitas Thol, MD, Tania Bunke, Dessislava Bogoeva, Christoph WM Reuter, MD, PhD, Arnold Ganser, Dirk Reinhardt, MD

Blood (2012) 120 (21): 1380.

https://doi.org/10.1182/blood.V120.21.1380.1380

Published: 2012

Journal Articles

Frequency and Prognostic Impact of NUP98/NSD1 Translocations in Adult AML and MDS Patients

Felicitas Thol, MD, Britta Kölking, Iris H.I.M. Hollink, MD, PhD, Frederik Damm, MD, Marry M. van den Heuvel-Eibrink, C. Michel Zwaan, MD, PhD, Gesine Bug, Oliver G. Ottmann, MD, Katharina Wagner, MD, Michael A Morgan, PhD, Wolf-Karsten Hofmann, Gudrun Göhring, MD, Brigitte Schlegelberger, Jürgen Krauter, Prof. Dr. med., Arnold Ganser, Michael Heuser, MD

Blood (2012) 120 (21): 1402.

https://doi.org/10.1182/blood.V120.21.1402.1402

Published: 2012

Journal Articles

Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes

Blood (2012) 119 (14): 3211–3218.

https://doi.org/10.1182/blood-2011-12-400994

Published: 2012

Includes: Supplemental data

Journal Articles

ID1 Expression Correlates with CEBPA Mutational Status and Is Not An Independent Risk Factor in Cytogenetically Normal AML,

Katharina Wagner, MD, Frederik Damm, MD, Michael A Morgan, PhD, Felicitas Thol, M.D., Haiyang Yun, Gudrun Göhring, MD, Brigitte Schlegelberger, M.D., Michael Heuser, M.D., Arnold Ganser, MD, Jürgen Krauter, MD

Blood (2011) 118 (21): 3554.

https://doi.org/10.1182/blood.V118.21.3554.3554

Published: 2011

Journal Articles

Modulation of Anthracycline-Induced Cytotoxicity by Targeting the Prenylated Prenylome in Myeloid Leukemia Cells

Michael A Morgan, PhD, Fredrick O Onono, Peter H Spielmann, Thangaiah Subramanian, Michaela Scherr, Letizia Venturinin, Iris Dallmann, Arnold Ganser, MD, Christoph W.M. Reuter

Blood (2011) 118 (21): 1418.

https://doi.org/10.1182/blood.V118.21.1418.1418

Published: 2011

Journal Articles

Prevalence and Clinical Effect of TET2 Mutations in Cytogenetically Normal Acute Myeloid Leukemia (CN-AML)

Birgit Markus, MD, Felicitas Thol, M.D., Michael A Morgan, PhD, Katharina Wagner, MD, Michael Heuser, M.D., Juergen Krauter, MD, Arnold Ganser, MD, Frederik Damm, MD

Blood (2011) 118 (21): 1448.

https://doi.org/10.1182/blood.V118.21.1448.1448

Published: 2011

Journal Articles

Favorable Prognostic Impact of WT1 SNP rs16754 in Cytogenetically Normal AML Independent of MN1, BAALC, and ERG Expression.

Frederik Damm, M.D., Juergen Krauter, Iyas Hamwi, Michael A. Morgan, Ph.D., Gudrun Goehring, Brigitte Schlegelberger, MD, Arnold Ganser, MD, Michael Heuser, MD

Blood (2009) 114 (22): 1622.

https://doi.org/10.1182/blood.V114.22.1622.1622

Published: 2009

Journal Articles

A Novel Proteomic Approach to Define Leukemia Cell Resistance to Farnesyltransferase Inhibitors.

Fredrick O. Onono, Ph.D., Michael A. Morgan, Ph.D., H. Peter Spielmann, Ph.D., Douglas A Andres, Ph.D., Michaela Scherr, Ph.D., Letizia Venturini, Ph.D., Iris Dallman, Arnold Ganser, MD, Christoph WM Reuter, M.D., Ph.D.

Blood (2009) 114 (22): 3761.

https://doi.org/10.1182/blood.V114.22.3761.3761

Published: 2009

Journal Articles

The Farnesyltransferase Inhibitor (FTI) L-778,123 Displays Promising Anti-Leukemia Activity

Fredrick O. Onono, Michael A. Morgan, Ph.D., Arnold Ganser, M.D., Ph.D., Christoph W. M. Reuter, M.D., Ph.D.

Blood (2008) 112 (11): 2627.

https://doi.org/10.1182/blood.V112.11.2627.2627

Published: 2008

Journal Articles

Potentiation of Topoisomerase II Inhibitor-Mediated Myeloid Leukemia Cell Kill by Farnesyltransferase Inhibitor L-744,832.

Fredrick O. Onono, MSc, Michael A. Morgan, PhD, Jeanny Wegner, MD, Arnold Ganser, MD/PhD, Christoph W.M. Reuter, MD/PhD

Blood (2007) 110 (11): 3479.

https://doi.org/10.1182/blood.V110.11.3479.3479

Published: 2007

Journal Articles

Characterization of a Novel R-RAS Mutation Cloned from Primary AML Cells.

Christoph W.M. Reuter, MD, PhD, Erdem Aydilek, MD, Fredrick O. Onono, Michael A. Morgan, PhD, Kristine A. Henningfeld, PhD, Arnold Ganser, MD/PhD

Blood (2006) 108 (11): 1439.

https://doi.org/10.1182/blood.V108.11.1439.1439

Published: 2006

Journal Articles

Prenylation Inhibitors Block IL-6 and IGF-1 Dependent Activation of RAS Signaling in Multiple Myeloma Cells.

Christoph W.M. Reuter, MD, PhD, Michael A. Morgan, PhD, Dietrich Peest, MD/PhD, Arnold Ganser, MD/PhD

Blood (2005) 106 (11): 3373.

https://doi.org/10.1182/blood.V106.11.3373.3373

Published: 2005

Journal Articles

Targeting RAS Signaling in Multiple Myeloma (MM): Synergistic Inhibition by Co-Treatment with the MEK Inhibitor U0126 and Prenylation Inhibitors.

Christoph W.M. Reuter, MD/Ph.D., Michael A. Morgan, Ph.D., Tarkan Sebil, Arnold Ganser, MD/Ph.D.

Blood (2004) 104 (11): 3398.

https://doi.org/10.1182/blood.V104.11.3398.3398

Published: 2004

Journal Articles

Cell-cycle–dependent activation of mitogen-activated protein kinase kinase (MEK-1/2) in myeloid leukemia cell lines and induction of growth inhibition and apoptosis by inhibitors of RAS signaling

Michael A. Morgan, Oliver Dolp, Christoph W. M. Reuter

Blood (2001) 97 (6): 1823–1834.

https://doi.org/10.1182/blood.V97.6.1823

Published: 2001

Journal Articles

Targeting the Ras signaling pathway: a rational, mechanism-based treatment for hematologic malignancies?

Christoph W. M. Reuter, Michael A. Morgan, Lothar Bergmann

Blood (2000) 96 (5): 1655–1669.

https://doi.org/10.1182/blood.V96.5.1655

Published: 2000

NARROW

High-Throughput Drug Screening Identifies Pyrimethamine As a Potent and Selective Inhibitor of Acute Myeloid Leukemia

NADH Dehydrogenase Subunit 4 ( ND4 ) Mutations in Pediatric Acute Myeloid Leukemia

Frequency and Prognostic Impact of NUP98/NSD1 Translocations in Adult AML and MDS Patients

Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes

ID1 Expression Correlates with CEBPA Mutational Status and Is Not An Independent Risk Factor in Cytogenetically Normal AML,

Modulation of Anthracycline-Induced Cytotoxicity by Targeting the Prenylated Prenylome in Myeloid Leukemia Cells

Prevalence and Clinical Effect of TET2 Mutations in Cytogenetically Normal Acute Myeloid Leukemia (CN-AML)

Favorable Prognostic Impact of WT1 SNP rs16754 in Cytogenetically Normal AML Independent of MN1, BAALC, and ERG Expression.

A Novel Proteomic Approach to Define Leukemia Cell Resistance to Farnesyltransferase Inhibitors.

The Farnesyltransferase Inhibitor (FTI) L-778,123 Displays Promising Anti-Leukemia Activity

Potentiation of Topoisomerase II Inhibitor-Mediated Myeloid Leukemia Cell Kill by Farnesyltransferase Inhibitor L-744,832.

Characterization of a Novel R-RAS Mutation Cloned from Primary AML Cells.

Prenylation Inhibitors Block IL-6 and IGF-1 Dependent Activation of RAS Signaling in Multiple Myeloma Cells.

Targeting RAS Signaling in Multiple Myeloma (MM): Synergistic Inhibition by Co-Treatment with the MEK Inhibitor U0126 and Prenylation Inhibitors.

Cell-cycle–dependent activation of mitogen-activated protein kinase kinase (MEK-1/2) in myeloid leukemia cell lines and induction of growth inhibition and apoptosis by inhibitors of RAS signaling

Targeting the Ras signaling pathway: a rational, mechanism-based treatment for hematologic malignancies?

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only